Mass spectrometry is an emerging format for label-free high-throughput screening. The main limitation of mass spectrometry is throughput, due to the requirement to purify samples prior to ionization. Here the authors compare an automated highthroughput mass spectrometry (HTMS) system (RapidFire™) with the scintillation proximity assay (SPA). The cancer therapy target AKT1/PKBα was screened against a focused library of kinase inhibitors and IC 50 values determined for all compounds that exhibit > 50% inhibition. A selection of additional compounds that exhibited ≤ 50% inhibition in the primary screen was chosen as controls to confirm inactives. The selection of compounds is expected to identify common actives, common inactives, false positives, and false negatives. Agreement is found between HTMS and SPA in terms of primary hit identification and hit confirmation. (Journal of Biomolecular Screening 2007:473-480) 
INTRODUCTION
L EAD IDENTIFICATION IS A VITAL STEP in the drug discovery process that provides the starting point for the medicinal chemistry optimization of potential development candidates. [1] [2] [3] Novel leads, as opposed to programs based on known compounds, are typically found by high-throughput screening (HTS) of compound libraries. Developments in HTS methodology have been instrumental in increasing the efficiency with which a wide range of receptor and enzyme targets can be screened against compound libraries. [1] [2] [3] Established capture HTS methods require the use of labeled substrates for either reactant or product capture and for detection. For example, scintillation proximity assay (SPA) technology requires a capture label such as biotin or a His-tag and a β-emitting detection label such as 33 P-labeled phosphate. The success of a particular assay format may be limited by the need to introduce molecular labels and by label interference with the primary reaction. Certain assay formats may also be suscepti-ble to compound interference, generating false positives or negatives in the primary screen. In addition, a requirement for labeled molecules may place unacceptable economic or pragmatic constraints on the ability to run a screen.
Mass spectrometry is an emerging format for label-free HTS. [4] [5] [6] [7] [8] The measurement is quite general, in that the reaction is monitored by a change in the mass of the substrate and product (either of the primary or daughter ions), allowing label-free reactants to be used. The primary physical limitation of mass spectrometry is the ability to generate detectable ions, which will vary based on the fundamental ionization properties of the analytes of interest and on the sample buffer. A liquid chromatography step is mandatory in electrospray mass spectrometry to remove nonvolatile salts and buffer components than can suppress ion formation. The use of conventional liquid chromatography systems restricts the typical throughput to 1 to 6 min per sample, 5, 8 which precludes the efficient screening of large compound libraries.
The RapidFire™ high-throughput mass spectrometry (HTMS) system provides a solution to the low throughput of traditional liquid chromatography systems. 7 RapidFire™ is a high-throughput robotic fractionation system coupled to an electrospray mass spectrometer with typical sample throughput times of 5 to 7 sec. 7 The system delivers samples directly from a 96-or 384-well screening plate to a chromatography system to remove buffer components and biological molecules. 7 The fractionated analytes are then delivered to an electrospray mass spectrometer for analysis. 7 Here we compare HTMS with SPA under HTS conditions using the Ser/Thr kinase AKT1 as a test case. AKT1, also called protein kinase Bα, is a downstream effector of the PI3K pathway implicated in oncogenesis and a topical target of interest in cancer drug discovery. 9 A current approach to improve HTS efficiency is to use small compound libraries that are focused on a specific enzyme class. 10 AKT1 was screened against a focused library of kinase inhibitors and IC 50 values determined for selected hits to identify common actives, common inactives, false positives, and false negatives. Agreement is found between HTMS and SPA in terms of primary hit identification and hit confirmation.
MATERIALS AND METHODS

Biological reagents
AKT1 was obtained from Upstate USA Inc. (Charlottesville, VA; catalog number 14-276). Biotin-AKTide (biotin-GGARKR-ERAYSFGHHA-NH 2 ) corresponds to the N-terminal α-amino biotinylated version of the AKT1 peptide substrate AKTide. 11 Biotin-AKTide and the phosphorylated Ser analog (pAKTide) were synthesized using Fmoc chemistry and purified with C 18 high-performance liquid chromatography (HPLC).
Scintillation proximity assay
Primary screening and dose-response SPA data were acquired at Bayer Pharmaceuticals Corporation (West Haven, CT). Assays were run at room temperature using a reaction buffer containing 50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 2 mM MnCl 2 , 1 mM DTT, and 0.01% bovine serum albumin (BSA). Compounds stored in 70% DMSO were diluted 100-fold in 20 µL of assay buffer in 384-well clear-bottom plates (final DMSO concentration 0.7%). AKT1 was added to a final concentration of 3 nM, and the reaction was initiated by adding a solution containing biotin-AKTide (0.6 µM final concentration), adenosine triphosphate (ATP; 1 µM final concentration), and 0.05 µCi [γ 33 P]ATP (PerkinElmer NEG/602H, PerkinElmer, Wellesley, MA). The reaction volume was 40 µL. The reaction was terminated after 180 min with 0.125 mg per well of streptavidin-coated SPA beads (Amersham RPNQ0007, Amersham, Pittsburgh, PA) in 10 µL of 150 mM EDTA. The final assay volume was 50 µL. Plates were centrifuged at 2 krpm for 5 min, and the radioactivity was measured with a Microbeta scintillation counter (PerkinElmer). In primary screening, compounds were present at 2.5 µM. In IC 50 determinations, compounds were dosed from 1 nM to 30 µM in half-log dilution steps.
Mass spectrometry
Primary screening and dose-response assays for HTMS analysis were run at Bayer Pharmaceuticals Corporation, as described for SPA, except that [γ 33 P]ATP and the SPA beads were omitted. After termination, plates were sealed, frozen at -80 °C, and shipped on dry ice to BioTrove Inc. (Woburn, MA) for analysis. At BioTrove, plates were thawed and immediately analyzed using the RapidFire™ system coupled to a Sciex API4000 triple quadrapole mass spectrometer. Both the substrate and product M 3+ ions were analyzed with electrospray mass spectrometry in positive-ion mode using multiplereaction monitoring. The sample (5 µL) was delivered directly from the plate to a proprietary clean-up cartridge (BioTrove column A) to remove nonvolatile assay components with 0.1% formic acid in a 3-sec wash cycle. The peptide substrate and phosphorylated product were coeluted to the mass spectrometer in 3 sec with 80% acetonitrile, 0.1% formic acid. The entire injection cycle was approximately 7.5 sec per well. The chromatography system produced baseline-resolved peaks with widths of approximately 2 sec.
The identities of compounds in individual wells or SPA results were not known to the mass spectrometry group.
Data analysis
The signal from SPA is the radioactivity content of the well, and the signal from HTMS is given by [P/(P + S)] × 100, where P and S are the product and substrate mass spectrum peak areas, respectively.
Enzyme inhibition is expressed as normalized percent inhibition, given by
where x is the signal for the test compound, and c -+ and c -− are the means of the positive (no inhibitor) and negative (no enzyme) controls (16 per plate), respectively.
IC 50 values are determined with nonlinear least squares fitting of the change in HTMS or SPA signal with inhibitor, assuming that the free ligand concentration approximates the total ligand concentration:
where y is the normalized percent inhibition at inhibitor concentration L, y f is the HTMS or SPA signal in the absence of inhibitor, y b is the HTMS or SPA signal in the presence of the saturating amount of inhibitor, and h is the Hill slope. Z′ is given by
where σ c+ and σ c-are the standard deviations of the positive and negative controls, respectively, and µ -c+ and µc− are the means of the positive (no inhibitor) and negative (no enzyme) controls (16 per plate), respectively. 12
RESULTS AND DISCUSSION
Assay development
AKT1 activity was assessed using a biotinylated version of the peptide substrate AKTide. 11 The phosphorylated peptide product was either captured with a streptavidin-coated bead in the SPA or detected directly with HTMS. Reaction conditions were identical for both assays, including use of the same biotinylated peptide substrate, although the use of labeled substrates is not required for the HTMS format.
HTMS methods development requires identification of ions of the peptide substrate and product. Both peptides yield good electrospray mass spectra for common fragments (m/z = 110) of the M 3+ primary ions (m/z = 676.3 and 702.6 for AKTide and pAKTide, respectively). The HTMS response is linear with peptide concentration (Fig. 1) , and HTMS spectra can be collected every 7.5 sec (Fig. 2) .
Product formation measured with HTMS and SPA is linear with time to 240 min at the screening AKT1 concentration of 3 nM ( Fig. 3) . Product formation is linear with time at the substrate screening concentration of 0.6 µM AKTide in both the HTMS and SPA formats (Fig. 4) . The SPA bead capacity appears limiting with respect to product detection at 1.2 µM AKTide in concordance with the manufacturer's specifications (Fig. 4B) . This dynamic range limitation is not, however, seen with HTMS ( Fig. 4A) . Analysis of the variation of initial velocity with substrate concentration measured with HTMS yields a K m of 0.8 ± 0.1 µM (Fig. 4C) , which is close to the screening substrate concentration of 0.6 µM.
Primary screen
The primary screen evaluated 1801 compounds from a focused library of kinase inhibitors with a single compound per Sample throughput is 7.5 sec. Each peak corresponds to a single injection from a different well with the product and substrate peaks detected from the same sample injection. The AKT1, AKTide, and adenosine triphosphate concentrations were 13 nM, 10 µM, and 100 µM, respectively, and chosen to provide essentially complete substrate turnover as opposed to the development of high-throughput screening conditions with lower substrate turnover. (C) Although individual peak heights may vary, the ratio of substrate and product peak area is consistent for a given time point (r 2 > 0.99).
well with replicates for each compound. Assays for each format were performed contemporaneously to ensure consistency of testing. Test compound removed from each library source plate was dispensed into 6 assay plates to enable triplicate testing of each compound in the 2 formats. In addition, bulk test reagents (i.e., buffers, substrate, enzyme) were contemporaneously dispensed from the same source. The only difference between the assays, aside from the quench step, was that SPA contained [γ 33 P]ATP in addition to nonradiolabeled ATP. The assay performance of both formats is good, with Z′ values in the range 0.6 to 0.8 for HTMS and 0.5 to 0.8 for SPA for 20 of 21 plates (Fig. 5) . Z′ values over 0.5 indicate that the assay is robust. 12 A total of 5403 measurements in each format were made on 1801 compounds in triplicate wells. Of these, 134 and 187 test samples elicited > 50% normalized percent inhibition in the HTMS and SPA formats, respectively. These hits are defined from single measurements, however. As with any variable, a more reliable assessment of hits is expected to be made when using averages of multiple measurements. Accordingly, a hit is defined as a compound that exhibits a mean percent inhibition from the 3 independent measurements of > 50%. A total of 47 compounds are active in the primary screen using these mean percent inhibition criteria. HTMS and SPA identify 38 and 46 hits, respectively, of which 37 are identified with both formats. Four structural classes and 9 singletons are represented, and members of each class are identified with both HTMS and SPA. There is a fair correlation over all compounds between the normalized percent inhibition observed by HTMS and SPA (r 2 = 0.76) (Fig. 6) . The correlation increases significantly (r 2 = 0.90) for active compounds defined by > 50% mean inhibition in the primary screen (Fig. 6) . The variation of the replicates for each assay is comparable, with neither assay exhibiting an apparently significant greater variation in replicate reproducibility (Fig. 6) .
Hit confirmation
All 47 compounds with a mean inhibition over 3 replicates of > 50% in 1 or both assay methods were selected for IC 50 determination. In addition, 23 compounds that exhibited a mean percent inhibition of ≤ 50% in either assay method were selected for IC 50 determination. Such compounds would not normally be followed up but were chosen as controls to confirm inactives and to provide examples of false negatives identified from historical SPA screens of AKT1. The 70 compounds are expected to provide a variety of confirmed hits, confirmed inactives, and false positives. In addition, because 2 formats are being compared, false negatives for 1 format can be identified based on detection in the 2nd format.
In general, there is good agreement between the mean IC 50 values determined from SPA and HTMS (r 2 = 0.94 for IC 50 values ≤ 2.5 µM, and r 2 = 0.90 for IC 50 values > 2.5 µM). All IC 50 values agree within 3-fold, and 67 of 70 IC 50 values agree to within 2-fold (Fig. 7) . The 3 IC 50 values that agree to within 3fold but not 2-fold are for compounds that are structurally distinct and unlikely to interfere with SPA.
There is good agreement between the ability of the 2 techniques to find common confirmed actives ( Fig. 8) . Of the 37 hits identified in the primary screen with both formats, 26 confirmed as actives in the dose-response studies with IC 50 values of 2.5 µM or less (corresponding to the primary screening concentration of the test compounds).
Because 2 techniques are being compared, it is feasible to identify false negatives of the primary screen for each technique from the pool of 23 compounds that were added to the doseresponse studies that were inactive in both assay formats, from the 1 hit identified only by HTMS, and from the 9 compounds identified only by SPA. Of these, the most unambiguous set of compounds exhibits IC 50 values ≤ 2.5 µM in both assay formats (Fig. 8) . From this set, HTMS and SPA identify 2 and 1 unique false negatives, respectively, and 4 common false negatives (Fig. 8) . With the exception of 1 HTMS false negative, the unique false negatives are on the borderline of the arbitrary hit criterion of > 50% inhibition (Fig. 8) . The 4 common false negatives originate from the selection of 23 additional compounds that were not identified as hits in this primary screen, and these specific 4 compounds have been historically active in SPA screens of AKT1. The presence of common false negatives identified by both methods suggests a systematic problem with these specific compounds, such as liquid-handling errors, and not with the assay formats. Overall, given that 4 common false negatives detected by both formats appear unrelated to assay format and were deliberately chosen based on historical SPA data, and that the 3 unique false negatives are close to the arbitrary hit criterion of > 50%, the false-negative rate due to assay format appears low. In addition, 6 compounds exhibit conflicting results in terms of the normalized percent inhibition or IC 50 values determined with the 2 assay formats in terms of the hit confirmation ( Table 1) . For example, compounds 1 to 3 are inactive in the HTMS primary screen (normalized percent inhibition ≤ 50%) but yield active compounds in the secondary dose-response screen (IC 50 ≤ 2.5 µM), with the converse observed for the SPA. Compound 4 is an apparent HTMS false negative but a confirmed SPA inactive, and compounds 5 and 6 are SPA false positives but confirmed HTMS actives. It is possible that a different choice of hit definition based on a numerical or statistical analysis of the primary hit data would alleviate some of these apparent discrepancies (or indeed may add further discrepancies). However, the existence of such a subset of compounds is expected in a high-throughput screen, given the number of assay-independent variables in addition to assay artifacts, and is only apparent when 2 formats are run contemporaneously as in the present study.
There is good agreement between HTMS and SPA in the identification of false positives (i.e., compounds with > 50% mean inhibition in the primary screen but with IC 50 values > 2.5 µM, corresponding to the compound screening concentration). Five unique SPA false positives are very close to the borderline for confirmed hit criteria, and no unique false positives are identified with HTMS ( Fig. 9) . Eight common false positives are detected by both HTMS and SPA (Fig. 9) , and the common identification suggests that these false positives are related to compound or liquid-handling issues rather than assay format, as discussed above for the common false negatives.
It is apparent that both SPA and mass spectrometry give close agreement in the measured IC 50 values and in the ability to identify confirmed hits. Neither format is unequally biased toward the identification of either false positives or false negatives. Indeed, most false negatives and positives are common to both formats, implying assay-independent sources of false result generation. Of the 70 compounds tested in the secondary screen, 85% give equivalent results in terms of being confirmed actives, confirmed inactives, false positives, or false negatives in both formats. Of the conflicting results, 6% of compounds are false positives or negatives in 1 format or the other, and 9% of compounds do not give unambiguous results ( Table 1) .
Implications for HTS
The present study was performed to evaluate the potential of HTMS as an HTS format. AKT1, a kinase that has been historically well characterized with in-house methods, was selected as a test case. The comparison of HTMS and SPA used a kinasefocused library containing drug-like compounds at a concentration of 2.5 µM. Inspection of the structures of confirmed hits and historical SPA data obtained with other kinases suggests that the likelihood of interference with the SPA format due to colored dye-like quencher molecules is small. In addition, differences in assay results due to library content and the state of the enzyme or substrate were minimized by performing the screens in an identical, contemporaneous fashion. Primary screening measurements of normalized percent inhibition were made in triplicate to reduce potential random errors that may be expected in singlepoint measurements in a full-file screen of hundreds of thousands of compounds or more. Indeed, the ability to reduce such errors by duplicate or triplicate primary screening measurements adds to the reliability and value of focused-file screens of smaller numbers of compounds and potentially adds to the agreement between 2 assay formats. Under these conditions, HTMS and SPA yield comparable outcomes in terms of primary screening hits and compounds that confirm as hits in secondary doseresponse testing.
This study has implications for the notion that assay format can greatly influence hit identification. [13] [14] [15] Different HTS formats have yielded disparate results when assay conditions such as buffer and reactant concentration were optimized for the different formats. 13, 14 Changes in assay parameters, such as buffer composition, substrate concentration, or enzyme/receptor concentration, may influence properties such as the thermodynamics and kinetics of compound binding, the ability of test compounds to compete with substrate, and changes in solubility or aggregation of either the enzyme or test compounds. In turn, these changes may affect the ability of a test compound to interact with the screening target, leading to the generation of false positives or negatives in the primary screen. Although certain assay formats, particularly those based on fluorescence, 16 may be more susceptible to compound interference than others, the present results and previous studies in which assay formats are compared under identical conditions [17] [18] [19] suggest that different HTS formats can yield similar screening results.
CONCLUSION
We conclude that high-throughput mass spectrometry yields similar HTS results for the Ser/Thr kinase AKT1, as obtained 
